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Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by gradual renal 
enlargement and cyst growth prior to the loss of renal function. The Consortium for Radiologic 
Imaging Studies in Polycystic Kidney Disease (CRISP) is a longitudinal observational study 
ADPKD individuals using high-resolution magnetic resonance (MR) imaging to determine if a 
change in renal and cyst volumes can be detected over a short period of time, and if they 
correlate with a decline in renal function early in the disease. The aim of this study was to 
determine if height-adjusted total kidney volume (htTKV) had a causal effect on renal decline in 
the CRISP cohort by using a method for causal inference, namely the generalized propensity 
score (GPS) method, which is a generalization of the more common propensity score methods 
(applicable to binary treatments or exposures) for continuous data. Results provide further 
evidence that baseline htTKV may have a causal effect on subsequent renal function (measured 
at least a decade later). The study did however have limitations, as we could only consider 
limited factors available at birth to construct the GPS (and thus preserve temporal associations).  
This study has a high degree of public health significance given the high incidence and 
cost of chronic kidney disease (CKD) and end stage renal disease (ESRD). CKD is identified as 
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a major public health concern requiring intervention, as nearly 20 million people are estimated to 
have CKD. ESRD also introduces a significant burden on patient, health care, and societal costs. 
Finding biomarkers that identify cases earlier are critical to reducing the disease burden. 
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1.0  INTRODUCTION 
1.1 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE 
Polycystic kidney disease (PKD) is an inherited disorder characterized by cystic expansion of the 
kidneys producing progressive kidney enlargement and renal insufficiency. Autosomal dominant 
polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease, 
occurring in 1 in 800 live births and the third most common single cause of end-stage renal 
disease (ESRD) in the United States.(1, 2) There are two types of ADPKD: type I is caused by 
mutations in the PKD1 gene and accounts for 85 to 90 percent of cases(3) and type II is caused by 
mutations in the PKD2 gene and accounts for 10 to 15 percent of cases.(4)  Type II disease has a 
later onset of symptoms and a slower rate of progression to renal failure; therefore patients have 
a longer life expectancy (69.1 years) than those with type I disease (53.0 years).(5)  Some patients 
with typical features of autosomal dominant polycystic kidney disease have no mutations in 
PKD1 or PKD2, suggesting that there may be a rare third form of the disease (6) although the 
proposed gene —PKD3— has not been identified. Patients often present with hypertension, 
hematuria, polyuria, and flank pain and are prone to recurrent urinary tract infections and renal 
stones. In addition to the presence of hundreds to thousands of renal cysts, clinically significant 
cysts are also common in the liver (especially in women), pancreas, and intestine. Patients 
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frequently experience complications involving various extrarenal manifestations, such as 
intracranial aneurysms, colon diverticular disease, and liver cysts. 
ADPKD is characterized by tremendous cystic growth of both kidneys resulting in 
bilateral kidney enlargement. Franz and Reubi(7) proposed that renal function remains stable in 
ADPKD patients for years, followed by a sharp decline once a critical renal size is reached. 
Increased renal volume predicts and is associated with loss of renal function in ADPKD.(8) 
However, standard radiographic imaging has not provided the resolution and accuracy necessary 
to detect small changes in renal volume or to reliably measure renal cyst volumes.  
Renal function is measured by glomerular filtration rate (GFR) as a continuous measure, 
or by categorizing GFR values below 60 as chronic kidney disease (CKD). GFR can either be 
estimated with equations based on serum creatatine, age, sex, and race, or measured directly with 
iothalamate clearance. Another outcome related to renal decline is ESRD, where the patient 
requires a transplant or dialysis; stage 5 CKD, where GFR is below 15, may also be grouped 
with ESRD. 
1.2 THE CRISP STUDY 
The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was 
established to develop innovative imaging techniques and analyses using magnetic resonance 
(MR) imaging to measure cyst and renal volume reliably and accurately in ADPKD individuals 
early in the course of their disease. The study started in 2001 and is concurrently ongoing. They 
enrolled 241 patients with ADPKD who were 15 to 46 years of age and who were evaluated 
annually (for a total of four visits) over a period of three years beginning in January 5, 2001. 
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CRISP was subsequently funded again in 2006, 2011, and 2017 (for 5 year periods). These 
subsequent 5-year periods included two to three clinic visits with subsequently described 
imaging and outcome measures. Eligible patients had received a diagnosis of ADPKD, had an 
actual or estimated (by the Cockcroft–Gault equation) creatinine clearance of at least 70 ml per 
minute, and had a serum creatinine level of 1.6 mg per deciliter (141 μmol per liter) or less in the 
case of male patients and 1.4 mg per deciliter (124 μmol per liter) or less in the case of female 
patients. Patients were ineligible if they had other medical conditions besides hypertension that 
could affect renal function (e.g., diabetes mellitus). The CRISP cohort study longitudinally 
observed ADPKD individuals using high-resolution magnetic resonance (MR) imaging to 
determine if change in renal and cyst volumes can be detected over a short period of time, and if 
they correlate with decline in renal function at early stage of the disease. 
The CRISP study showed that MR measures of renal and cyst volume are reliable and 
accurate in patients with ADPKD. ADPKD is characterized by significant cystic involvement 
that increases with age. Structure (renal and cyst volume) and function (GFR) are inversely 
related and directly related with the presence of hypertension and urinary albumin excretion in 
individuals with normal renal function.(9) During the initial CRISP study period of 3 years, 
CRISP found that kidney enlargement resulting from the expansion of cysts in patients with 
ADPKD is continuous and quantifiable. Total kidney volume and total cyst volume increased 
exponentially, and the baseline total kidney volume predicted the subsequent rate of increase in 
volume, independently of age. Higher rates of kidney enlargement are associated with a more 
rapid decrease in renal function.(10)  At the baseline initial study visit, adult men had greater 
mean TKV than adult women with a ratio of 1.15. In order to correct for other factors 
influencing, TKV was referenced initial study to baseline height, weight, body surface area, or 
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BMI in order to diminish the sex differences. From this analysis, height was the best reference 
for TKV (htTKV), with a male/female ratio of 1.037 and was used thereafter in CRISP study.(11)  
CRISP reported with 8 years of follow-up had found increasingly strong associations between 
baseline htTKV and the follow-up iothalamate clearances and progression through the K/DOQI 
stages.(11) These observations demonstrate that renal cyst burden, reflected by htTKV, is a very 
important determinant of renal functional decline in ADPKD. 
This current analysis seeks to better assess causal effects of htTKV on renal decline. So 
far, the methods used in CRISP, and in other studies of predictors of renal function, have used 
generalized linear models (including mixed models for repeated longitudinal measurements) to 
assess associations. For this study, we consider htTKV as the exposure or “treatment” and 
describe and apply the concept of the generalized propensity score to better estimate the average 
causal effect. Estimating causal effects is challenging in observational studies, since the 
treatments of interest (e.g., screening by echocardiography and use of antidepressants in 
pregnancy) are not randomly allocated, and important characteristics differ between groups. 
Similarly, htTKV may be related to other factors that confound the association with the outcome. 
Direct comparisons of the outcomes between treated and untreated groups, or by kidney volume 
in CRISP, would have likely resulted in significantly biased estimates.  
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1.3 THE POTENTIAL OUTCOME FRAMWORK FOR CAUSAUL INFERENCE 
1.3.1 Association versus Causation 
Most analyses of observational studies examine the association between an exposure (e.g., a 
food, something in the environment, or a biomarker) and an outcome (often a disease or death). 
Because of all the other exposures occurring simultaneously in the complex lives of free-living 
humans that can never be completely accounted for, such studies cannot provide evidence of 
cause and effect using standard statistical methods. In other words, without using special 
methods for causal inference in the setting of a well-designed observational study, such studies 
cannot distinguish direction–whether exposure A influences outcome B, or B influences A, or 
both are influenced by something else, even if that association may be strong and consistent. In 
CRISP study, based on the data what we can say is: Increased kidney volume is associated with 
subsequently decreased renal function. But we want to say that increased volume causes 
subsequently decreased renal function. In order to use kidney volume as a surrogate marker for 
ADPKD, i.e. as a measure that can substitute for the outcome, we have to establish the causation 
between them. 
1.3.2 The Potential Outcomes Framework for Causal Inference 
Causal inference is the process of drawing a conclusion about a causal connection based on the 
conditions of the occurrence of an effect. A number of different frameworks exist for causal 
inference, and the assumptions depend on the framework being utilized. For this analysis, we 
define causal effects in terms of  potential outcomes. (12)  Briefly, in the simple case of a 
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dichotomous treatment with two levels A and B, the individual causal effect (which cannot be 
directly estimated) is defined as the difference between the observed outcome and the other 
potential outcome, i.e. the counterfactual (or some function of that difference depending on the 
outcome distribution). Say individual i receives treatment A at time 0; the outcome measured at 
time 1 is denoted as Yi (A). The potential (unobserved) outcome for individual i on treatment B 
is defined as Yi (B). We can then define the average treatment effect (ATE) as the expectation of 
those differences: ATE = E [Yi (A) - Yi (B)].  
 
 
                                         Figure 1. The concept of potential outcomes 
 
In randomized trial studies, the ATE can be estimated without bias by simple differences 
in the group A and group B mean outcomes since treatments are assigned randomly. However, in 
observational studies, the causal effects (ATE) are not estimated by the simple difference in 
expectations: ATE ≠E [Yi (A)| X] – E [Yi (B)| X], because the propensity to one treatment versus 
another is typically affected by many other factors, such as the physician choice, patient factors 
and institutional factors. 
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1.4 METHODS FOR ESTIMATING TREATMENT EFFECTIVENESS 
A wide range of methods are available for analyzing treatment effectiveness from observational 
data to reduce or eliminate the effects of confounding factors, such as stratifying results by a 
single or multiple covariates using standard statistical tests or statistics. For example, the 2×2 
contingency tables were extended to multiple contingency tables with arbitrarily many rows 
and/or columns, where rows and columns are orderable, and may even be on a continuous scale. 
With scores assigned, a deviation of the sum of cross products from expectation, and its variance 
conditioned on all marginal totals, are computed for each table and a chi square is determined 
corresponding to the grand total of the deviations. The procedure extends or is equivalent to the 
asymptotic form of many known non-parametric techniques.(13)  
A second approach is to match subjects on a specific characteristic(s) of interest and 
conduct paired analyses. For example a paired samples t-test based on a matched-pairs sample, 
which results from an unpaired sample that is subsequently used to form a paired sample, by 
using additional variables that were measured along with the variable of interest.(14) The 
matching is carried out by identifying pairs of values consisting of one observation from each of 
the two samples, where the pair is similar in terms of other measured variables. This approach is 
sometimes used in observational studies.  
A third approach is to use regression models. Historically, applied researchers have relied 
on the use of regression adjustment to account for differences in measured baseline 
characteristics between treated and untreated subjects. Logistic regression is a commonly used 
method to control for imbalances between groups. Its primary advantage is the ability to control 
for many variables simultaneously.(15)  
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The first two approaches offer very limited flexibility in terms of the number of potential 
confounders and manner in which the variable is characterized. The third method is also 
problematic of the above if too many variables need to be included in a model relative to the 
number of events, the estimates from these models can be incorrect. Regression and stratification 
methods also do not provide unbiased estimates of causal effects.(16) 
One set of approaches that better estimate the causal effect under more realistic 
assumptions are propensity score (PS) methods. The propensity score was defined by 
Rosenbaum and Rubin (17)  to be the probability of treatment assignment conditional on observed 
baseline covariates. The propensity score is a balancing score: conditional on the propensity 
score, the distribution of measured baseline covariates is similar between treated and untreated 
subjects. Thus, in a set of subjects all of whom have the same propensity score, the distribution 
of observed baseline covariates will be the same between the treated and untreated subjects. PSs 
are typically estimated with a logistic regression model that regresses the exposure variable on 
observed confounders. The estimated propensity score is the predicted probability of treatment 
derived from the fitted regression model. PS methods enable the investigators to create study 
groups that were similar to one another and more accurately measure the relationship between 
treatment and outcome.  
Four different propensity score methods are most commonly used for removing the 
effects of confounding when estimating the effects of treatment on outcomes: matching on the 
propensity score, stratification on the propensity score, inverse probability of treatment 
weighting (IPTW) using the propensity score, and covariate adjustment using the propensity 
score (18). Propensity score matching entails forming matched sets of treated and untreated 
subjects who share a similar value of the propensity score. Stratification on the propensity score 
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involves stratifying subjects into mutually exclusive subsets based on their estimated propensity 
score. Typically, subjects are stratified based on quantiles of the propensity score. Subjects are 
ranked according to their estimated propensity score. Subjects are then stratified into subsets 
based on previously defined thresholds of the estimated propensity score. IPTW using the 
propensity score uses weights based on the propensity score to create a synthetic sample in 
which the distribution of measured baseline covariates is independent of treatment assignment. 
With Covariate adjustment using the propensity score, the outcome variable is regressed on an 
indicator variable denoting treatment status and the estimated propensity score. The choice of 
regression model would depend on the nature of the outcome. These propensity score methods 
allow one to design and analyze an observational study so as to mimic some of the characteristics 
of a randomized study.(19) 
Much of the work on propensity score analysis has focused on the case where the 
treatment is binary. Imbens extends the method to the multi-group to reduce bias in observational 
studies where treatment can have several levels.(20)  His work involves calculating an average 
treatment effect by weighting observations by the inverse of the probability of treatment level 
actually observed. Jiang and colleagues have used both binary and multi-group approaches to 
study the effects of breastfeeding initiation and duration on child cognitive outcomes.(21)  The 
generalized propensity score (GPS) for continuous treatments is a straightforward extension of 
the well-established and widely used propensity score methodology for binary treatments and 
multi-valued treatments. Similar to the binary and multivalued treatment propensity score 
methods, it is assumed that – conditional on observable characteristics – the level of treatment 
received can be considered as random. In a setting in which doses (usually treatment) are not 
administered under experimental conditions, estimation of a dose-response function (outcome) is 
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possible using the GPS. Hirano and Imbens show that the GPS has a balancing property similar 
to the balancing property of the "classic" propensity score.(22)  This implies that individuals 
within the same strata of the GPS should be identical in terms of their observable characteristics, 
independent of their level of treatment. 
1.5 THE AIM OF THIS STUDY 
In this study we examined an extension to the propensity score method: the GPS method, in a 
setting with a continuous measure, which is a biomarker (baseline htTKV) rather than a 
treatment or exposure. However, the use of the GPS applies equally well to the case of this 
biomarker as it does for the originally developed application of continuous treatment doses. We 
assessed the causal relationship between htTKV and progression of ADPKD (as measured by 
GFR at least a decade later) using a subgroup of the CRISP cohort study. To accomplish this, we 
apply essentially the same method as developed for estimating a dose-response function as 
proposed in Hirano and Imbens.(22)  Specifically, in this study we estimated the causal 
relationship between the continuous response of GFR across the range of values of the 
continuous htTKV. In terms programming the method, we used a set of Stata programs to 
estimate the GPS, test whether the estimated GPS satisfies the balancing property, and predicted 
the dose–response function. We estimated the ADPKD patients’ average GFR after at least 10 
years from baseline. Participants were also included if they reached end-stage renal disease 
(ESRD). Baseline htTKV was recorded when they were enrolled in the study. These estimates 
were adjusted for differences in characteristics available at birth (to maintain temporal 
associations) using the generalized propensity score methodology. 
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2.0  METHODS 
2.1 THE STUDY DESIGH 
CRISP is a prospective, longitudinal cohort study, which began in 2001 and is currently ongoing. 
The data in this paper covered the study period until to 2014. CRISP enrolled participants ages 
15 to 46 years who met the following criteria: (1) Diagnosis of ADPKD; (2) Actual or estimated 
creatinine clearance of at least 70 mL/min; (3) Serum creatinine level of ≤ 1.6 mg/deciliter for 
men and ≤ 1.4 mg/deciliter for women. Patients were ineligible if they had other medical 
conditions besides hypertension that could affect renal function (e.g., diabetes mellitus).The 
initial study enrolled 241 participants. Enrollees were interviewed by telephone every 6 months 
and were evaluated in standardized fashion during clinic visits every 12 months. Total kidney 
volume (TKV) and glomerular filtration rate (GFR) were measured each of the first 3 years of 
the study and approximately every 2 years thereafter. TKV was measured by MRI(23)  and 
referenced to height (htTKV, cc/m). GFR was measured by a nonradiolabeled iothalamate 
clearance technique with sonographic monitoring of bladder emptying (24)  and was referenced to 
body surface area adjusted to a fixed norm (milliliters per minute per 1.73 m2). Our primary 
outcome was the GFR at the last visit for each subject (which was usually at 10-12 years after 
baseline). For subjects who reached ESRD at any time in the study, a value of 10 was imputed 
for their GFR, since it is effectively 10 at the time of kidney failure. For this analysis, we 
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excluded participants who were lost-to-follow-up (i.e. did not have a GFR and imaging 
measurement) before 10 years and did not yet reach ESRD.   
There were a total of 186 participants who were followed for at least ten years or they 
reached the endpoint of end-stage renal disease (ESRD). CRISP includes a wide range of 
variables on demographics, medical conditions and hospitalizations, imaging measures (which 
includes htTKV), and urine and serum biomarkers measured at baseline and (for most variables) 
at the clinic visits. However, this analysis concentrates on variables which were measured at 
birth since we can definitively say they occurred before, and are not a result of, the patient’s 
htTKV. More specifically, among the variables in the original data set, we chose gender, race, 
genotype (PKD1, PKD2, or no mutation detected), truncation (yes or no for whether the 
mutation includes frame shifting, nonsense or splicing) and birth season, which were the only 
variables that were from birth. The htTKV measurement was the main predictor of interest.  
2.2 STATISTICAL ANALYSIS 
2.2.1 Descriptive analyses 
Means, standard deviations (SDs), minimum values, maximum values, medians and interquartile 
ranges (displayed as the median [IQR]) were provided to describe htTKV and GFR values over 
time. Gender, race, genotype, truncation and birth season were categorical variables and 
described as frequencies and percentages.  
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2.2.2 Associations with htTKV and GFR 
To assess the association of each covariate with baseline htTKV and last visit GFR, simple linear 
regression models were fitted between gender, genotype, truncation, race, birth season and 
htTKV, GFR respectively. These analyses were part of the process of calculating the GPS, as 
described below. The coefficients were reported. 
2.3 THE GENERALIZED PROPENSITY SCORE METHOD 
2.3.1 GPS definition 
As described in the introduction, the GPS is a variation of traditional propensity methods where 
we model the probability of treatment (T) given patient characteristics. In the binary treatment 
case, we postulate for each individual there are the potential outcomes Yi(t), for t ϵT, here 
T=(0,1). However, for a continuous treatment T is an interval [t0, t1] and we are interested in the 
average dose-response function, u(t) = E [Yi(t)]. 
Let r (t, x) be the conditional density of the treatment given the covariates X: r (t, x) = f T |X (t |x). 
The generalized propensity score (R) is then defined as  
(1)          R = r (T, X).  
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2.3.2 Assumption of the GPS 
The key assumption of Hirano and Imbens (22) generalizes the unconfoundedness assumption for 
binary treatments made by Rosenbaum and Rubin (17) to the continuous case: 
(2)          Y (t) ┴ T | X for all t ϵ T 
It is referred as weak unconfoundedness as we do not require joint independence of all 
potential outcomes, {Y(t) }(25) t ϵ[t0, t1]. Instead, we require conditional independence to hold for 
each value of the treatment. 
The GPS has a balancing property similar to the balancing property of the propensity 
score for binary treatments. Within strata with the same value of r (t,X) the probability that T=t 
does not depend on the value of covariates X.  
This is an implication of the definition of the GPS and does not require weak 
unconfoundedness. In combination with weak unconfoundedness, it implies that assignment to 
treatment is unconfounded given the GPS. It has been showned that if assignment to treatment or 
exposure (or in our case the value of kidney volume) is weakly unconfounded given covariates 
X, then it is also weakly unconfounded given the GPS(22). 
2.3.3 The procedures of GPS method 
Given the result that if assignment to treatment is weakly unconfounded given covariates X, then 
it is also weakly unconfounded given the GPS, it is possible to use the GPS to remove bias 
associated with differences in covariates in the following steps (16).  To be consistent with the 
notation in the literature on GPS, we refer to treatment, denoted by Ti, but the same approach 
applies to estimating causal effects of the biomarker value.   
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2.3.3.1 Model and estimation of the GPS 
We assume a normal distribution for the baseline htTKV given the covariates.  
(3)          Ti |Xi ~ N (β0 + β1’Xi,σ2)   
We use normal Quantile-Quantile (Q-Q) plots to check the normality of htTKV. Since 
htTKV was not normal (see Results), data was then be log transformed to give the following 
equation: 
(4)          log Ti |Xi ~ N (β0 + β1’Xi,σ2) 
In the simple normal model we can estimate β0, β1, and σ2 by maximum likelihood. The 
estimated GPS was calculated as 
(5)         i =  exp (-  (Ti - 0- '1Xi)2 ) 
2.3.3.2 Removal of bias by using the generalized propensity score 
In the case of a continuous measurement it is also crucial to evaluate how well adjustment for the 
GPS works in balancing the covariates. 
We assessed the covariates’ balance by using K square test before the GPS adjustment, as 
suggested by Hirano and Imbens (22). We divided the sample into three groups according to the 
distribution of length of baseline htTKV, cutting at 33th, 66th percentile. For each of the 
covariates, we investigated the balance by testing whether the frequency in one of the three 
treatment groups was different from the rest of the other samples.  
Then we investigated how GPS affected the balance of the covariates. In the binary case 
the typical approach is to compare the covariate means for the treated and control units before 
and after matching, testing for covariate balance is more difficult with continuous measurements. 
We followed Hirano and Imbens' approach of "blocking on the score".  
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First, the sample was divided into three groups as described above. Within each group, 
we evaluated the GPS at the median of htTKV. In the second step we divided each group into 
five blocks by the quintiles of the GPS evaluated at the median. Within each of these blocks, we 
calculated the difference-in-means of covariates with respect to individuals that had a GPS such 
that they belonged to that block, but had a htTKV level different from the one being evaluated. 
This procedure tested for each of these blocks whether the covariate means of individuals 
belonging to the particular htTKV-level group were significantly different from those of 
individuals with a different htTKV level, but similar GPS. A weighted average over the five 
blocks in each htTKV level group can be used to calculate the t-statistic of the differences-in-
means between the particular htTKV level group and all other groups. The procedure needed to 
be repeated for each of htTKV level group and for each covariate. If adjustment for the GPS 
properly balances the covariates, we would expect all those differences-in-means not to be 
statistically different from zero.  
2.3.3.3 Estimate the conditional expectation of the outcome 
With the GPS method, we estimated the conditional expectation of the outcome last visit’s GFR 
as a function of two scalar variables, the htTKV level T and the GPS R, i.e. 
(6)          β(t,r)= E[Y |T = t,R= r] . 
For the estimation of the equation, we had to assume some functional form of the 
relationship between the last GFR Y, the htTKV level T, and the GPS R.  
Following the general approach proposed by Hirano and Imbens, we assessed the 
correlation pattern between GFR and Ti (htTKV), GFR and GPS (Ri) respectively, and tested for 
addition of the interaction term of T and R. Depending on those results, we then choose one of 
the following polynomials. 
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(7)         E(Yi | Ti, Ri)= α0 + α1Ti + α2Ti2 + α3Ri + α4Ri2 + α5TiRi 
(8)         E (Yi | Ti, Ri)= α0 + α1Ti + α2Ti2 + α3Ti3 + α4Ri + α5Ri2 + α6Ri3 + α7TiRi + α8Ti2Ri 
+ α9TiRi2 
2.3.3.4 Estimate the dose-response function at each particular level of the treatment 
This is implemented by averaging the conditional expectation function over the GPS at that 
particular level of the treatment, 
(9)      μ (t)= E[β(t,r(t,X))] 
The procedure does not average over the GPS R=r (T, X), but instead it averages over the 
score evaluated at the htTKV level of interest r(t,X).  
For each individual the observed htTKV (Ti) and estimated GPS i were used, and the 
equation was estimated by ordinary least squares. Given the estimated parameters, if we used a 
quadratic approximation, the average potential outcome at htTKV level t was estimated as: 
(10)    =  0 + 1 t + 2 t2 3   (t, Xi) + 4   (t, Xi)2 + 5  Xi ))  
 where  is the vector of the estimated parameters in the second stage. 
The above function can then be obtained by estimating this average potential outcome for 
each level of the treatment. In our application, we used bootstrap methods to obtain standard 
errors that take into account estimation of the GPS and α parameters, i.e. we bootstrapped the 
entire estimation process. 
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3.0  RESIUTS 
3.1 BASELINE CHARACTERISTICS 
The mean of baseline htTKV was 638.13 cc/m, the minimum was193.82 cc/m, the maximum 
was 2113.12 cc/m, and the median was 507.37 cc/m. The mean of last visit’s GFR was 62.87 
ml/min per 1.73m2, from the minimum value of 10 ml/min per 1.73m2 to the maximum value of 
172 ml/min per 1.73m2 (Table 1). 
Among the participants, 59.14% was female, 79.89% was PKD1 mutation, 69.94% of the 
patients had gene truncation, 10.75% was black and about 20-30% were born at each of the four 
seasons (Table 2). 
 
Table 1. Summary statistics of the variables htTKV and last visit’s GFR 
Variable n Mean Min Q25 Q50 Q75 Max 
htTKV(cc/m) 186 638.13 193.82 362.15 507.37 848.57 2113.12 







Table 2. Summary statistics of baseline characteristics 
Variable Frequency Percent (%) 
Gender* 
Male 75 40.9 
Female 110 59.1 
Genotype* 
NMD/PKD2 37 20.1 
PKD1 146 79.9 
Truncation 
Non-Truncating 51 30.1 
Truncation 121 69.9 
Race 
Others 166 89.3 
Black 20 10.8 
Season 
Spring 54 29.0 
Summer 41 22.0 
Fall 55 29.6 
Winter 36 19.4 
 
Note: Gender: * one missing observation; ** three missing observations. 
3.2 REGRESSION COEFFICIENTS TEST 
Among the baseline characteristics, only genotype is significant associated with baseline htTKV 




Table 3. Association between each of the covariates and htTKV 
Variable Coef. P value 
Gender -56.83 0.329 
Genotype 212.49 0.003 
Truncation 13.56 0.836 
Race -65.50 0.483 
Season* 
Spring -47.38 
0.931 Fall -48.81 
Winter -30.47 
                                                                    
Note: *With Summer as the baseline 
 
Table 4. Association between each of the covariates and outcome of GFR 
Variable Coef. P value 
Gender 6.30 0.311 
Genotype -17.82 0.019 
Truncation 5.35 0.448 
Race 12.90 0.189 
Season* 
Spring 10.71 
0.590 Fall 8.70 
Winter 9.63 
Note: *With Summer as the baseline 
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3.3 THE APPLICATION OF GPS 
3.3.1 Modelling the conditional distribution of htTKV given the covariates 
The distribution of the htTKV was skewed with a skewness of 1.40 and a kurtosis of 4.77. The 
Q-Q plots also showed a systematic deviation from normality. We therefore used a log 
transformation. The logarithm of the htTKV was approximately normal with a skewness of 0.29 
and a kurtosis of 2.31 (Figure2 and 3). We then used a normal linear model for the logarithm of 
htTKV. 
 
Histogram                                                              Q-Q plots 
  









Histogram                                                              Q-Q plots 
  
Figure 3. Histogram and Q-Q plots of htTKV after logarithms transformation 
 
The estimated coefficients (GPS Est) and standard error of GPS in model (4) are 
presented in Table 5.  There is no direct meaning to the estimated coefficients in this model, 
except that testing whether all coefficients for the GPS were equal to zero can be interpreted as a 
test whether the covariates introduce any bias. 
Table 5.  Estimated coefficients for the GPS 
Variable GPS Est. GPS SE 
Intercept 6.218 0.1672 
Gender -0.088 0.0854 
Genetype 0.2628 0.1196 
Truncation 0.0106 0.0906 
Race -0.0774 0.1440 
Season* 
Spring -0.0819 0.1172 
Fall -0.1135 0.1181 
Winter -0.0650 0.1332 
 
Note: *With Summer as the baseline 
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3.3.2 Removal of bias by using the generalized propensity score 
In the case of a continuous measurement it is also crucial to evaluate how well adjustment for the 
GPS works in balancing the covariates. We assessed the covariates’ balance by using K square 
test before the GPS adjustment.  
In Table 6, we reported the k square test for each of the five covariates in each of the 
three groups before GPS adjustment. The results showed 4 statistic tests had significant 
differences. 
 
Table 6.  Balance of the covariates: k square test for equality of frequency 
Variable 
Unadjusted: chi2 (p) 
[0; 395.15] [395.15;697.83 ] [697.83; 2113.12] 
Gender 0.37(0.541) 0.09(0.769) 0.80(0.371) 
Genetype 7.40(0.007) 0.08(0.774) 8.84(0.003) 
Truncation 0.08(0.783) 0.01(0.963) 0.04(0.826) 
Race 7.52(0.006) 5.28(0.022) 0.19(0.660) 
Season 
Spring 0.87(0.351) 1.28(0.258) 0.04(0.843) 
Summer 0.85(0.357) 0.03(0.866) 1.16(0.282) 
Fall 2.88(0.089) 1.08(0.299) 0.42(0.515) 
Winter 0.01(0.939) 0.01(0.939) 0.02(0.880) 
 
Then we investigated how GPS affects the balance of the covariates. After the adjustment 
for the GPS, none of the p values were greater than 0.05, showing that the GPS eliminated any 
significant imbalances (Table 7). 
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Table 7.  Balance given the generalized propensity score: t-statistics for equality of medians 
Variable 
Adjusted for GPS: t (p) 
[0; 395.15] [395.15;697.83 ] [697.83; 2113.12] 
Gender 0.723(0.235) -0.532(0.702) -0.718(0.763) 
Genetype 1.414(0.795) -0.297(0.617) -1.211(0.886) 
Truncation -0.151(0.560) 0.014(0.494) -0.199(0.579) 
Race -1.028(0.847) 1.522(0.065) -1.153(0.875) 
Season 
Sping 0.623(0.267) -1.145(0.873) 0.973(0.166) 
Summer -0.192(0.576) 0.195(0.423) -1.304(0.568) 
Fall -0.991(0.161) 1.037(0.151) -0.172(0.568) 
Winter 0.552(0.291) 0.044(0.482) 0.162(0.436) 
3.3.3  Model the conditional expectation of Yi and Ri 
We checked the correlation pattern between GFR and Ti (htTKV), GFR and GPS (Ri) 
respectively, to determine whether to use linear regression or non-linear regression. From figure 
4 we can see, GFR and Ti were negative non-linear correlated. Figure 5 showed that GFR and Ri 
were positive and non-linear correlated. Therefore we used a quadratic approximation of Ti and 
Ri. Because Ri and Ti are in opposite direction (Figure 4 and Figure 5), an interaction term of Ti 





Figure 4. Fitted curve of GPS and GFR 
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Figure 5. Fitted curve of htTKV and GFR 
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3.3.4 Averaging the estimated regression function over the score function evaluated at the 
desired level of the htTKV 
The estimated GFR over each value of htTKV was obtained by estimating the average potential 
outcome (last visit GFR) over possible values of baseline htTKV. The equation (10) in 3.34 of 
“methods” section was used in this procedure. In our application, we use bootstrap methods to 
obtain standard errors that take into account estimation of the GPS and α parameters, i.e. we 
bootstrap the entire estimation process. 
Figures 6 shows the shape for estimated GFR outcomes based on the baseline htTKV, 
which indicates a negative correlation between baseline htTKV and last visit’s GFR. As we 
would expect, the expected GFR decreases with increasing htTKV until leveling out at higher 
kidney volumes. The apparent increase near the end is likely chance with little data and wide 
confidence intervals in that range. The estimated curve shows that if htTKV value is more than 
520 cc/m at the first visit, participants would progress to at least stage 3 CKD or an 
GFR<60ml/min per 1.73m2 in 10 years.  
 
Figure 6. Expected GFR and Confidence Interval Based on the GPS 
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4.0  CONCLUSION AND DISCUSSION 
Kidney enlargement resulting from the expansion of cysts in patients with ADPKD is continuous 
and quantifiable and is associated with the decline of renal function. Usually physicians and 
patients monitor changes in serum creatinine levels to determine the extent of progression. 
However, serum creatinine levels do not typically rise in patients with ADPKD until the fourth 
or fifth decade of life, after the noncystic parenchyma has incurred serious, irreversible damage. 
Therefore, creatinine levels are usually ineffective for early detection and prevention. Our results 
showed that the larger values of baseline htTKV appear to have a causal relationship with 
subsequent renal decline within the following decade. Therefore, htTKV offers a high potential 
for earlier detection and may be very useful for prevention efforts and early interventions to 
reduce incidence of ESRD. htTKV may therefore also be useful in clinical practice and for risk 
stratification in designing clinical trials for this disorder. 
There are several practical reasons for preferring the use of propensity score based 
methods to regression-based methods when estimating treatment effects using observational 
data. First, it is simpler to determine whether the propensity score model has been adequately 
specified than to assess whether the regression model relating treatment assignment and baseline 
covariates to the outcome has been correctly specified.(19) The diagnosis of whether the 
propensity score model has been adequately specified diagnostics were based on comparing the 
distribution of measured baseline covariates between treated and untreated subjects. In contrast, 
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it is much more difficult to determine whether the regression model relating treatment selection 
and baseline covariates to the outcome has been correctly specified. Goodness-of-fit measures, 
such as model R2, do not provide a test of whether the outcome model has been correctly 
specified. Furthermore, goodness-of-fit tests do not allow one to determine the degree to which 
the fitted regression model has successfully eliminated systematic differences between treated 
and untreated subjects. Second, it has been reported that approaches using the propensity score 
estimate less biased estimators than regression analysis when there are seven or fewer events per 
confounder variable in simulation studies.(26) Moreover, the propensity score approaches do not 
need unrealistic assumptions to estimate causal effects in an unbiased manner, and these 
estimates are robust with regard to model misspecification.(27)  
In this study, we applied the approach developed by Hirano and Imbens(22) who propose 
estimating the entire dose-response function (DRF) of a continuous treatment. This approach fits 
perfectly with the objective of our analysis, since we are interested in the response (declining 
renal function) associated with each value of the continuous measure of htTKV. Alternatively we 
could categorize the continuously distributed variable for volume and apply propensity score 
methods for multi-valued treatments. But the GPS has the advantage that it makes use of the 
entire information contained in the distribution of htTKV. The GPS has balancing properties that 
can be used to assess the adequacy of particular specifications of the score.  
In summary, this study illustrates the use of the GPS for making inferences about levels 
of a biomarker and its causal effects on renal function. While the variables we collected at birth 
were limited and often not significantly associated with the outcome, the study still serves to 
illustrate the use of this method in the setting of a continuous biomarker, which is a novel 
application of these methods. Future studies should explore considering other variables which 
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are measured earlier in life (but after birth) that may still precede kidney growth. The 
significance of these methods and the CRISP study is emphasized by continuing interest in 





















APPENDIX A. DOSE-RESPONSE FUNCTION ANALYSIS WITH AGE 
STRATIFICATION 
Polycystic kidney disease is a life-long condition, the cysts start grow at birth and patients reach 
ESRD at the median age of 54 years old for PKD1 mutation and 74 years for PKD2 mutation. As 
we showed in this study that the larger values of baseline htTKV appear to have a causal 
relationship with renal decline possibly a decade later. So we suspect that those subjects with an 
earlier age of onset of an enlarged htTKV would have a more severe disease and hence earlier 
age of onset of renal impairment than subjects who manifested the disorder later in life. 
Therefore we stratified our observations into two sets by median age 44.7 years old ( Table 8), 
and obtained expected GFR based on the GPS ( dose-response function analysis) and the results 
were shown at figure 7. 
Figure 7 indicated a negative correlation between baseline htTKV and last visit’s GFR: 
slowly and monotonously decreasing GFR response to the increasing of the htTKV in both of the 
younger than median age and older than median ones. With the same baseline htTKV, the 
participants in the older group had a lower last visit GFR than the younger group, indicating that 
age was an important factor in determining renal function.  
The graphs also showed that the slope of figure 7a was deeper than figure 7b, which 
indicated that those subjects with an earlier age of onset of enlarged kidney volume would have a 
more severe disease and hence earlier age of onset of renal impairment than subjects who 
manifested the disorder later in life. It was also shown that children with onset in utero or in the 
first year of life appeared to do worse.(25, 28)  
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Table 8. Summary statistics of the variable age 
Variable n Mean Min Q25 Q50 Q75 Max 
Age (Year) 186 44.08 26.41 28.37 44.70 51.18 59.15 
 
 
              Figure 7a.Age younger than median age                           Figure 7b. Age older than median age 
     











APPENDIX B. STATA CODE 
use "C:\Users\Yaming\Desktop\Thesis\Yaming thesis dataset4.dta" ,clear 
 *clean data 
 sort pkdid vis 
 by pkdid: gen httkv0=httkv[1]  
 by pkdid: gen N=_N 
 by pkdid: gen n=_n 
 keep if n==N 
 keep if visc>=10 | esrd==1 
 drop cic_c race gender birthdate genetype trunc_grp race4 httkv brwgt UMOD_creat months 
httkv_18 N n 
 * Summary statistics of  htTKV and last visit’s GFR 
sum httkv0 LastGFR, detail 
* Summary statistics of  baline characteristics 
gen summerseason=0 
replace summerseason=1 if Fallseason==0 & winterseason==0 & Springseason==0 
tabulate gender1  
tabulate genetype1  
tabulate trunc_grp1  
tabulate race1  
tabulate Springseason 
tabulate summerseason  
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tabulate Fallseason  
tabulate winterseason 
*Normality test 







*regression coefficciants test 
reg lnhttkv gender1 genetype1 trunc_grp1 race1 
foreach v of varlist gender1 genetype1 trunc_grp1 race1 { 
reg  httkv0 `v' 
} 
foreach v of varlist gender1 genetype1 trunc_grp1 race1 { 
reg LastGFR `v' 
} 
reg httkv0 i.seasons 
reg LastGFR i.seasons 
* Balance test bedore GPS 
egen p33 = pctile( httkv0 ), p(33) 
egen p66 = pctile( httkv0 ), p(66) 
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quietly generate cut = 395.15 if httkv0<=395.15 
quietly replace  cut = 697.84 if httkv0>395.15 & httkv0<=697.84 
quietly replace  cut =2113.12  if httkv0>697.84 
tab cut 
gen group=1 if cut<=395.15 
replace group=2 if cut<=697.85 & cut>395.15   
replace group=3 if cut>697.85  
gen group1=1 if group==1 
replace group1=2 if group==2 | group==3  
gen group2=1 if group==1 | group==2 
replace group2=2 if group==3  
gen group3=1 if group==1 | group==3 
replace group3=2 if group==2  
tab cut 
foreach v of varlist gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason { 
tabulate  group1 `v', chi2 
} 
foreach v of varlist gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason { 
tabulate  group2 `v', chi2 
} 
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foreach v of varlist gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason { 
tabulate  group3 `v', chi2 
}  
*dose-response function test 
gpscore gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason,t(httkv0) gpscore(gpscore) predict(y_hat) sigma(sd) cutpoints(cut) index(p50) 
nq_gps(5) t_transf(ln) detail 
drop sd  
doseresponse gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason, outcome(LastGFR)t(httkv0)gpscore(psore) predict(hat_treat) sigma(sd) 
cutpoints(cut) index(p50) nq_gps(5) t_transf(ln) dose_response(dose_response) npoints(160) 
delta(1) reg_type_t(quadratic) reg_type_gps(quadratic) interaction(1) bootstrap(yes) 
boot_reps(100) filename("output_wide") analysis(yes) graph("graph_output_wide") detail 
 
sort httkv0 
twoway lowess LastGFR httkv0 
sort lnhttkv 
twoway lowess LastGFR lnhttkv 
*Stratified by age 
use "C:\Users\Yaming\Desktop\Thesis\Yaming thesis dataset4.dta" ,clear 
sum age, detail 
keep if age<=44.7 
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egen p33 = pctile( httkv0 ), p(33) 
egen p66 = pctile( httkv0 ), p(66) 
gpscore gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason,t(httkv0) gpscore(gpscore) predict(y_hat) sigma(sd) cutpoints(cut) index(p50) 
nq_gps(5) t_transf(ln) detail 
drop sd  
doseresponse gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason, outcome(LastGFR)t(httkv0)gpscore(psore) predict(hat_treat) sigma(sd) 
cutpoints(cut) index(p50) nq_gps(5) t_transf(ln) dose_response(dose_response) npoints(160) 
delta(1) reg_type_t(quadratic) reg_type_gps(quadratic) interaction(1) bootstrap(yes) 
boot_reps(20) filename("output_wide") analysis(yes) graph("graph_output_wide") detail 
use "C:\Users\Yaming\Desktop\Thesis\Yaming thesis dataset4.dta" ,clear 
keep if age>44.7 
egen p33 = pctile( httkv0 ), p(33) 
egen p66 = pctile( httkv0 ), p(66) 
gpscore gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason,t(httkv0) gpscore(gpscore) predict(y_hat) sigma(sd) cutpoints(cut) index(p50) 
nq_gps(5) t_transf(ln) detail 
drop sd  
doseresponse gender1 genetype1 trunc_grp1 race1 Springseason summerseason Fallseason 
winterseason, outcome(LastGFR)t(httkv0)gpscore(psore) predict(hat_treat) sigma(sd) 
cutpoints(cut) index(p50) nq_gps(5) t_transf(ln) dose_response(dose_response) npoints(160) 
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delta(1) reg_type_t(quadratic) reg_type_gps(quadratic) interaction(1) bootstrap(yes) 
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